Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Ovarian Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 4Fallopian Tube Neoplasms 4Breast Neoplasms 4Multiple Myeloma 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Primary Myelofibrosis 2Neoplasms 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioblastoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Vulvar Neoplasms 1Vaginal Neoplasms 1

Interventions

Decitabine 4Cyclophosphamide 4ruxolitinib 3fludarabine phosphate 3Filgrastim 3Etoposide 3Topotecan 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Methylprednisolone 2LY2784544 2Cytarabine 2Carboplatin 2Antilymphocyte Serum 2veliparib 1umbralisib 1tipifarnib 1talazoparib 1spartalizumab 1sonidegib 1sargramostim 1sabatolimab 1romidepsin 1pyroxamide 1peginterferon alfa-2a 1nelarabine 1navitoclax 1fresolimumab 1durvalumab 1arsenous acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Polycythemia Vera × Immunoglobulin G × Clear all
NCT02871323 2019-08-20

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Northwestern University

Phase 1 Withdrawn
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡